Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Datamonitors' C&O Pharmaceutical Technology (Holdings) Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by C&O Pharmaceutical Technology (Holdings) Limited since January 2007.
– Provides intelligence on C&O Pharmaceutical Technology (Holdings) Limited's M&A, strategic partnerships and alliances, capital raising and private equity transactions. – Detailed reports of various financial transactions undertaken by C&O Pharmaceutical Technology (Holdings) Limited and its subsidiaries since 2007. – Information about key financial and legal advisors for C&O Pharmaceutical Technology (Holdings) Limited's financial deals transactions. – Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
This report includes C&O Pharmaceutical Technology (Holdings) Limited's contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by C&O Pharmaceutical Technology (Holdings) Limited. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Reasons to Purchase:
– Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances. – Form an independent opinion about C&O Pharmaceutical Technology (Holdings) Limited’s growth strategies through the organic and inorganic activities undertaken since 2007. – Track your competitors’ business structure and growth strategies.
Our reports have been used by over 10K customers, including:
Real-world data and real-world evidence are used to monitor the post-market safety and adverse events of drugs.The monitoring of this data assists in making regulatory decisions. The healthcare community is using RWE and RWD to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice. The...
45 pages •
By CCM Information Science & Technology Co., Ltd
• Jul 2021
If you subscribe annually, you can get a better price Vitamins China E-News provides you with real-time intelligence on China’s vitamins market. It is a monthly published newsletter, which can be downloaded in PDF format. The subscription period is yearly, grants the subscriber 12 issues in total. China...
5-Hydroxytryptamine Receptor 6 - Drugs In Development, 2021 Summary According to the recently published report ’5-Hydroxytryptamine Receptor 6 - Drugs In Development, 2021’; 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 15 molecules. Out...
The global instrument calibrator market is expected to grow from US$ 1,277.57 million in 2021 to US$ 1,854.03 million by 2028; it is estimated to grow at a CAGR of 5.5% during 2021–2028. Calibration is the process of comparing unknown values obtained for devices under test (DUT) to a known value reference standard.In pharmaceutical...
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drugs In Development, 2021 Summary According to the recently published report ’Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021’; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5...
What’s Ahead for the Pharmaceutical Industry?--Emerging Opportunities and Growth Strategies for Suppliers The series includes current assessments of more than 1,000 companies worldwide. Depending on the company’s business nature and structure, the assessments include all or some of the following analyses: Organization...
This IDC Perspective provides IDC Health Insights' overview of key IT deals, news, and digital initiatives in the European life sciences and pharma industries in Q1 2021. In the evolving COVID-19 scenario, it is critical for European life sciences companies and their technology suppliers to closely follow the fast-moving trends and developments...
230 pages •
By Asia Market Information & Development Company
• Aug 2021
China’s demand for Heparin has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.